New findings from the KATHERINE trial, published in The New England Journal of Medicine, confirm that trastuzumab emtansine (T-DM1) continues to provide superior survival benefits over trastuzumab alone in HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.
With 8.4 years of follow-up, T-DM1 demonstrated:
✅ 54% reduction in invasive disease recurrence or death compared to trastuzumab alone.
✅ 7-year invasive disease-free survival: 80.8% vs. 67.1%.
✅ 7-year overall survival: 89.1% vs. 84.4%.
✅ Improved long-term outcomes despite a higher rate of grade 3+ adverse events.
These results further reinforce T-DM1 as the preferred adjuvant therapy in this high-risk group, setting a new standard for care in early-stage HER2+ breast cancer.
Thanks to the researchers and clinical teams behind this study for their dedication to advancing breast cancer treatment. Their work continues to shape clinical practice and improve patient outcomes.
Read more about the study: https://lnkd.in/ease4zDn
